Opko Health, Inc. (OPK)
AI stock analysis · as of Jul 30, 2026
Loading microstructure…
OPKO Health is a diversified but persistently unprofitable healthcare company straddling specialty diagnostics (BioReference, being reshaped after selling non-core assets to Labcorp for up to $462.5M) and pharmaceuticals, with a Pfizer-partnered growth hormone (NGENLA), Rayaldee, and an early-stage ModeX multispecific antibody pipeline. The core investment question is whether NGENLA royalty economics, a leaner BioReference, and ModeX optionality can outrun continued operating losses (-$225.7M FY25 net loss, -$190.8M FCF) and refinancing needs before the balance sheet ($369M cash vs $397M debt, D/E 33.6x) forces dilution.
valuationOptically cheap on P/B (0.86x) and P/S (1.7x), but that reflects genuine distress — negative EBITDA (EV/EBITDA -14.3x), -37% net margin, and -15% revenue growth — so 'fair' at best, with option value rather than earnings support.
This analysis is from Jul 30, 2026. Want the latest on OPK, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Analyst consensus target of $4.375 (range $3–$8.50) implies ~220% upside from $1.365, with H.C. Wainwright reiterating Buy at $3 and an average 'buy' rating from 4 covering analysts.
- · NGENLA is expanding across 50+ markets with Pfizer commercializing, and label extensions (e.g., Small for Gestational Age) could scale OPKO's royalty/gross profit share into a high-margin annuity.
- · Balance-sheet reshaping: up to $462.5M from Labcorp divestitures plus April 2025 convertible note exchange gives runway to fund ModeX without immediate equity raise.
- · Deep optionality in the pipeline — MDX2001 already at 5th dose level Phase 1, MDX2003/2004 first-in-human in 2026, plus Merck EBV vaccine collab (first patient dosed Jan 2025) and BARDA non-dilutive funding for infectious disease work.
- · Trades at 0.86x book and 1.7x sales — well below typical specialty pharma multiples — with insiders holding ~50.5%, aligning management with equity holders (no net insider selling in past 180 days).
- · Elevated short interest (7.94% of float, 10.8 days to cover) sets up squeeze potential on any positive clinical or licensing catalyst.
Bear case
- · Revenue is shrinking, not growing: FY2025 revenue of $607M is down 14.9% YoY from $713M, and down ~30% from $863M in FY2023 — the divestiture strategy is masking a structural top-line contraction.
- · Losses widened materially: FY25 net loss of -$225.7M (net margin -37.2%) is 4x wider than FY24's -$53.2M, and free cash flow is deeply negative at -$190.8M.
- · Balance sheet is fragile — total debt of $397M essentially offsets $369M cash, D/E is 33.6x, and multiple convertible tranches (2025, 2029, 2044 notes) create refinancing complexity flagged in the 10-K.
- · GuruFocus flags the stock as 19–23% overvalued on GF Value, and the recent post-earnings pop reversed 11–17% the next session, signaling weak conviction from marginal buyers.
- · PEG of 93.65 and forward P/E of -5.0 highlight that current price already discounts substantial future growth that has yet to materialize; ModeX assets are early-stage with binary outcomes.
- · Structural governance/legal overhangs: 2022 Corporate Integrity Agreement with HHS-OIG, key-man dependency on the Chairman/CEO, and reimbursement pressure on Rayaldee and 4Kscore.
Catalysts
- · Next earnings on 2026-07-27 — watch for NGENLA royalty growth trajectory and BioReference margin improvement post-divestiture.
- · ModeX Phase 1 readouts: MDX2001 dose escalation data and MDX2003/MDX2004 first-in-human initiations in 2026.
- · Rayaldee international launch progress (Macau 2025, mainland China regulatory submission, European expansion).
- · Potential further monetization of non-core diagnostics assets or new licensing/partnership deals following the Regeneron collaboration (October 2025).
- · Short squeeze setup: 7.94% short float and 10.8 days to cover on a sub-$2 stock can amplify moves on any positive catalyst.
- · Convertible note refinancing execution — successful refi removes a major overhang; failure/dilution is a downside catalyst.
Key risks
- · Continued cash burn (~$190M annually) against ~$369M cash implies ~2-year runway absent monetization events, raising dilution or refinancing risk.
- · Clinical failure or delay in ModeX pipeline would remove the primary long-term equity story.
- · Reimbursement pressure and further pricing/utilization cuts on diagnostics services and Rayaldee.
- · Regulatory/legal exposure under the ongoing HHS-OIG Corporate Integrity Agreement.
- · Key-man risk concentrated in the Chairman/CEO, explicitly cited in the 10-K.
- · FX and geopolitical exposure via operations in Spain, Chile, Mexico, and Israel.
What to watch
- · Q2 2026 earnings on July 27, 2026 — revenue trajectory, NGENLA royalty growth, and cash burn rate.
- · Cash runway commentary and any convertible note refinancing announcements.
- · MDX2001 Phase 1 dose-escalation updates and MDX2003/MDX2004 first-in-human initiations.
- · Technical levels: $0.98 52-week low as key support; $1.73 52-week high as resistance; watch for squeeze dynamics given 10.8 days-to-cover.
- · Any incremental sell-side actions — last downgrade was Barrington Research (Apr 2025); no upgrades/downgrades in the past 90 days.
- · Regeneron collaboration milestones and additional partnership/licensing announcements.
Key metrics
Price target rationale
Base case $2.00 applies ~2.5x P/S to a stabilizing ~$600M revenue base plus modest pipeline option value, in line with peer specialty pharma with negative earnings. Bull case $4.00 assumes NGENLA royalty inflection, positive ModeX Phase 1 signal, and successful refi — roughly aligned with street mean. Bear case $0.90 (below 52-week low) reflects dilutive capital raise, continued revenue erosion, and ModeX setback.
On Wall Street's view (mixed): The $4.375 consensus mean (with $8.50 high) looks aggressive given accelerating losses and declining revenue, though the $3 low end from H.C. Wainwright is defensible if NGENLA royalties scale and ModeX shows early clinical validation. I see a base case closer to $2 with meaningful two-way risk.
Latest filing (10-K)
OPKO is a cash-burning diversified healthcare company pivoting from a sprawling diagnostics business toward a Pfizer-partnered growth hormone royalty stream and an early-stage multispecific antibody pipeline, funded partly by selling off BioReference assets to Labcorp for up to $462.5 million.
OPKO Health is a diversified healthcare company operating two segments: pharmaceuticals and diagnostics. The pharmaceutical segment commercializes NGENLA (somatrogon, a once-weekly growth hormone partnered with Pfizer), Rayaldee (an FDA-approved CKD/vitamin D treatment), and a pipeline of multispecific antibodies via subsidiary ModeX Therapeutics, plus established pharma platforms in Spain, Ireland, Chile, and Mexico. The diagnostics segment operates BioReference Health, a specialty clinical laboratory focused on the New York/New Jersey region and the proprietary 4Kscore prostate cancer test after divesting non-core assets to Labcorp for up to $462.5 million in aggregate consideration.
What the news says · neutral
OPKO Health reported Q2 2026 earnings that beat revenue estimates and showed shrinking losses, triggering an initial sharp post-earnings rally to near 52-week highs. However, the stock gave back roughly 11-17% the very next session, suggesting the move was overdone and profit-taking set in quickly. Valuation concerns are a headwind, with GuruFocus flagging the stock as 19-23% overvalued on its GF Value metric. On the positive side, H.C. Wainwright reiterated a Buy with a $3 target and the company initiated Phase 1 trials in B-Cell Lymphoma and COVID prevention, keeping pipeline optionality alive. The net picture is a volatile, speculative name where near-term enthusiasm faded fast against a backdrop of ongoing losses and stretched valuation.
This analysis is from Jul 30, 2026. Markets move. Get the current read on OPK and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.